Literature DB >> 27598809

Direction Modulated Brachytherapy for Treatment of Cervical Cancer. II: Comparative Planning Study With Intracavitary and Intracavitary-Interstitial Techniques.

Dae Yup Han1, Habib Safigholi2, Abraam Soliman2, Ananth Ravi3, Eric Leung4, Daniel J Scanderbeg5, Zhaowei Liu6, Amir Owrangi3, William Y Song7.   

Abstract

PURPOSE: To perform a comprehensive comparative planning study evaluating the utility of the proposed direction modulated brachytherapy (DMBT) tandem applicator against standard applicators, in the setting of image guided adaptive brachytherapy of cervical cancer. METHODS AND MATERIALS: A detailed conceptual article was published in 2014. The proposed DMBT tandem applicator has 6 peripheral grooves of 1.3-mm width, along a 5.4-mm-thick nonmagnetic tungsten alloy rod of density 18.0 g/cm(3), capable of generating directional dose profiles. We performed a comparative planning study with 45 cervical cancer patients enrolled consecutively in the prospective observational EMBRACE study. In all patients, MRI-based planning was performed while utilizing various tandem-ring (27 patients) and tandem-ring-needles (18 patients) applicators, in accordance with the Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology recommendations. For unbiased comparisons, all cases were replanned with an in-house-developed inverse optimization code while enforcing a uniform set of constraints that are reflective of the clinical practice. All plans were normalized to the same high-risk clinical target volume D90 values achieved in the original clinical plans.
RESULTS: In general, if the standard tandem was replaced with the DMBT tandem while maintaining all other planning conditions the same, there was consistent improvement in the plan quality. For example, among the 18 tandem-ring-needles cases, the average D2cm(3) reductions achieved were -2.48% ± 11.03%, -4.45% ± 5.24%, and -5.66% ± 6.43% for the bladder, rectum, and sigmoid, respectively. An opportunity may also exist in avoiding use of needles altogether for when the total number of needles required is small (approximately 2 to 3 needles or less), if DMBT tandem is used.
CONCLUSIONS: Integrating the novel DMBT tandem onto both intracavitary and intracavitary-interstitial applicator assembly enabled consistent improvement in the sparing of the OARs, over a standard "single-channel" tandem, though individual variations in benefit were considerable. Although at an early stage of development, the DMBT concept design is demonstrated to be useful and pragmatic for potential clinical translation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27598809     DOI: 10.1016/j.ijrobp.2016.06.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Needle-free cervical cancer treatment using helical multishield intracavitary rotating shield brachytherapy with the 169 Yb Isotope.

Authors:  Karolyn M Hopfensperger; Quentin Adams; Yusung Kim; Xiaodong Wu; Weiyu Xu; Kaustubh Patwardhan; Bounnak Thammavong; Joseph Caster; Ryan T Flynn
Journal:  Med Phys       Date:  2020-03-13       Impact factor: 4.071

Review 2.  Imaging-guided brachytherapy for locally advanced cervical cancer: the main process and common techniques.

Authors:  Zhongshan Liu; Yangzhi Zhao; Yunfeng Li; Jing Sun; Xia Lin; Tiejun Wang; Jie Guo
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  A directional 103Pd brachytherapy device: Dosimetric characterization and practical aspects for clinical use.

Authors:  Mark J Rivard
Journal:  Brachytherapy       Date:  2016-12-28       Impact factor: 2.362

4.  Efficient 169 Yb high-dose-rate brachytherapy source production using reactivation.

Authors:  Ryan T Flynn; Quentin E Adams; Karolyn M Hopfensperger; Xiaodong Wu; Weiyu Xu; Yusung Kim
Journal:  Med Phys       Date:  2019-05-27       Impact factor: 4.071

5.  High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option.

Authors:  Rajendra Bhalavat; Vibhay Pareek; Manish Chandra; Lalitha Nellore; Karishma George; Dipalee Borade; Ketan Kalariya; Zaiba Moosa; Amrita Srivastava; Navaneeth Reddy; Ankita Kapoor; Darshana Kawale; Nandakumar P; Pratibha Bauskar
Journal:  J Contemp Brachytherapy       Date:  2018-10-15

6.  Influence of dwell time homogeneity error weight parameter on treatment plan quality in inverse optimized high-dose-rate cervix brachytherapy using SagiPlan.

Authors:  Mohammad Amin Mosleh-Shirazi; Elham Shahcheraghi-Motlagh; Mohammad Hadi Gholami; Alireza Shakibafard; Sareh Karbasi; Reza Fardid
Journal:  J Contemp Brachytherapy       Date:  2019-06-28

Review 7.  In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice.

Authors:  Gabriel P Fonseca; Jacob G Johansen; Ryan L Smith; Luc Beaulieu; Sam Beddar; Gustavo Kertzscher; Frank Verhaegen; Kari Tanderup
Journal:  Phys Imaging Radiat Oncol       Date:  2020-09-28

Review 8.  Evolution of Brachytherapy Applicators for the Treatment of Cervical Cancer.

Authors:  Ankur Mourya; Lalit Mohan Aggarwal; Sunil Choudhary
Journal:  J Med Phys       Date:  2021-12-31

9.  Magnetic resonance image-based 3D volume interstitial brachytherapy using polyether ether ketone catheters in advanced cervical cancer - a feasibility study.

Authors:  Siddanna Rudrappa Palled; Chitradurga Abdul Razak Tanvirpasha; Thimmaiah Naveen; Saminathan Sathiyan; Ganesh Kadirampatti; Vishwanath Lokesh
Journal:  J Contemp Brachytherapy       Date:  2019-08-29

10.  Comparison of two inverse planning algorithms for cervical cancer brachytherapy.

Authors:  Qi Fu; Yingjie Xu; Jing Zuo; Jusheng An; Manni Huang; Xi Yang; Jiayun Chen; Hui Yan; Jianrong Dai
Journal:  J Appl Clin Med Phys       Date:  2021-02-24       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.